Since its approval by the European Medicines Agency (EMA) in June 2021, Wegovy represents a major breakthrough in the treatment of obesity. This semaglutide-based medication, developed by Novo Nordisk, offers new hope to millions of people struggling with obesity in Europe and worldwide.
Unlike temporary solutions, Wegovy acts on the fundamental biological mechanisms of appetite regulation, thus ushering in a new era in the medical management of obesity. Let’s explore this revolutionary treatment, its proven efficacy, and important considerations to be aware of.
What is Wegovy and how does it work?
Wegovy is an injectable medication containing semaglutide at a dose of 2.4 mg, specifically formulated for the treatment of obesity. Semaglutide belongs to the family of GLP-1 receptor agonists, molecules that mimic the action of a hormone naturally produced by the intestine.
Wegovy’s mechanism of action is based on several synergistic effects:
- Slowing of gastric emptying: food remains in the stomach longer, prolonging the feeling of fullness
- Appetite regulation: direct action on hunger control centers in the brain
- Improved insulin sensitivity: optimization of glucose metabolism
- Reduced food cravings: decrease in urges for high-calorie foods
Unlike Ozempic, which contains the same molecule but at lower doses to treat diabetes, Wegovy is specifically dosed and approved for weight management in overweight or obese adults.
Clinical Efficacy: Remarkable Scientifically Validated Results
Wegovy’s efficacy data comes from the STEP (Semaglutide Treatment Effect in People with obesity) clinical study program, which included over 4,500 participants worldwide.
Results of the STEP 1 Study
The pivotal STEP 1 study, published in the New England Journal of Medicine in 2021, demonstrated exceptional results:
- Average weight loss: 14.9% of initial body weight over 68 weeks
- More than a third of participants (35%) lost at least 20% of their initial weight
- 83.5% of patients achieved a weight loss of at least 5%
- Improvement in metabolic parameters: reduction in blood pressure, improvement in lipid profile
Long-term Data and Complementary Studies
STEP 2, 3, and 4 studies confirmed Wegovy’s efficacy in different populations, including prediabetic and type 2 diabetic patients. A follow-up study published in 2024 in The Lancet showed sustained weight loss over 104 weeks in patients continuing treatment.
More recently, the SELECT study, published in 2024, revealed significant cardiovascular benefits, with a 20% reduction in major cardiovascular events in patients treated with semaglutide.
Safety Profile and Side Effects to Be Aware Of
Wegovy’s safety has been evaluated in over 5,000 patients in clinical trials. Like any medication, it can cause adverse effects that should be known.
Common Side Effects
The most commonly reported adverse effects are primarily gastrointestinal:
- Nausea (44% of patients) – generally temporary
- Diarrhea (30% of patients)
- Vomiting (24% of patients)
- Constipation (24% of patients)
- Abdominal pain (20% of patients)
These effects are generally mild to moderate and tend to decrease over time. Gradual dose escalation helps minimize their impact.
Precautions and Contraindications
Wegovy is contraindicated in patients with:
- A personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Ongoing acute pancreatitis
- An allergy to semaglutide
Regular medical monitoring is essential, especially at the start of treatment.
Access to Treatment: Prescription, Price, and Reimbursement
Prescription Conditions
Wegovy is available by medical prescription only. In France, it can be prescribed to adults with:
- A BMI ≥ 30 kg/m² (obesity)
- A BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea syndrome)
Treatment must be part of a comprehensive management plan including nutritional support and adapted physical activity.
Economic Situation and Reimbursement
The price of Wegovy varies across European countries, ranging between 200 and 400 euros per month. In France, discussions with health authorities for potential reimbursement have been ongoing since 2024.
Several European countries have already integrated Wegovy into their reimbursement systems under certain conditions, recognizing obesity as a chronic disease requiring appropriate medical management.
Availability and Supply
Since 2024, the supply of Wegovy has been gradually improving in Europe after initial supply tensions. Novo Nordisk has significantly increased its production capacities to meet the growing demand.
It is essential to obtain Wegovy exclusively through official pharmaceutical channels and to be wary of counterfeits circulating online.
Conclusion: A Therapeutic Revolution Under Medical Supervision
Wegovy undeniably represents a major breakthrough in the treatment of obesity, with unprecedented clinical results and a well-documented safety profile. Recent scientific data, particularly the cardiovascular benefits demonstrated in 2024, reinforce the therapeutic interest of this treatment.
However, Wegovy is not a miracle solution and requires rigorous medical supervision. Optimal efficacy is achieved within a comprehensive management plan combining lifestyle modifications, nutritional follow-up, and regular physical activity.
It is imperative to consult a healthcare professional to evaluate the indication, potential benefits, and individual risks before considering this treatment. Only a doctor can determine if Wegovy is suitable for your personal situation and ensure the necessary medical follow-up.
The future looks promising with ongoing developments in next-generation GLP-1 agonists, foreshadowing new therapeutic options for the millions of people affected by obesity.